To receive future news releases direct to your inbox, subscribe by emailing

Historical news and financial information can also be found at under the Company’s profile.

2019 2018 2017 2016 2015 2014
Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019
Resverlogix Announces Voting Results from the 2019 Annual Meeting of Shareholders
Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
Resverlogix Announces US$12 Million Debenture Financing and Full Repayment of Loan
Resverlogix to Host BETonMACE Webcast and Conference Call
Resverlogix Announces BETonMACE Trial Results Accepted for Presentation at American Heart Association’s Scientific Sessions 2019
Resverlogix Provides Update on BETonMACE Phase 3 Trial
Resverlogix Announces Annual and Special Meeting of Shareholders
Resverlogix to Present at the European Society of Cardiology’s ESC Congress 2019
Resverlogix Announces Loan Reduction and Extension
Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
Resverlogix Provides Update on BETonMACE Phase 3 Epigenetics Trial
Resverlogix Announces Participation at Leading, International Scientific Conferences
Resverlogix Announces Closing of $15 Million Offering
Resverlogix Announces Pricing of Unit Offering
Resverlogix Announces Proposed Offering of Units
Resverlogix Announces Publication on Apabetalone in High-Impact American Journal of Respiratory and Critical Care Medicine (AJRCCM)
Resverlogix Announces 3-Month Loan Extension
Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
Resverlogix Announces $15.1 Million of Private Placements
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
Resverlogix Announces Participation at Prominent Industry and Investor Conferences
Resverlogix Closes $6.6 Million Private Placement with Shenzhen Hepalink